Addex Therapeutics Ltd
ADXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.09 | 0.34 |
| FCF Yield | -103.46% | -253.96% | -374.90% | -45.19% |
| EV / EBITDA | -0.41 | 0.17 | 0.21 | -0.84 |
| Quality | ||||
| ROIC | -27.88% | -110.90% | -199.41% | -82.94% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.76 | 0.76 | 0.79 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -34.26% | -17.92% | -26.71% | 1.82% |
| Free Cash Flow Growth | 32.81% | 51.34% | -11.54% | -20.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 1.61 | 0.63 | 1.34 |
| Interest Coverage | -776.78 | -103.81 | -215.57 | -246.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14.01 | 34.23 | 153.53 | 40.60 |